Entering text into the input field will update the search result below

T2 Biosystems' (TTOO) CEO John McDonough on Q4 2017 Results - Earnings Call Transcript

Mar. 06, 2018 9:53 PM ETT2 Biosystems, Inc. (TTOO)2 Comments
SA Transcripts profile picture
SA Transcripts

T2 Biosystems (NASDAQ:TTOO) Q4 2017 Earnings Conference Call March 6, 2018 4:30 PM ET


Chris Brinzey - IR

John McDonough - CEO

John Sprague - CFO

Tom Lowery - CSO


Steve Brozak - WBB

Patrick Donnelly - Goldman Sachs

Mark Massaro - Canaccord Genuity

Puneet Souda - Leerink Partners

Carolina Ibanez-Ventoso - Janney Montgomery Scott

Yi Chen - H.C. Wainwright

Matthew Cross - Jones Trading


Greetings and welcome to the T2 Biosystems' 2017 fourth quarter and year-end financial results conference call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Chris Brinzey. Thank you. You may begin.

Chris Brinzey

Thank you, operator and good evening, everyone. Thanks for joining us for the T2 Biosystems 2017 fourth quarter and year-end financial results conference call. On the call to discuss the results and operational highlights for the period ended December 31, 2017 are President and CEO, John McDonough; Chief Financial Officer, John Sprague; and Chief Scientific Officer, Tom Lowery. The executive team will open the call with some prepared remarks followed by a question-and-answer period.

Before we begin, I'd like to remind everyone that comments made by management today will include forward-looking statements. Those include statements related to T2 Biosystems' future, financial and operating results and plans for developing and marketing new products. Forward-looking statements are based on estimates and assumptions as of today and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by those statements, including the risks and uncertainties described in T2 Biosystems' Annual Report on Form 10-K filed with the SEC on March 15, 2017. The company undertakes no obligation to publicly update

Recommended For You

Comments (2)

JrMastermind profile picture
Do we have any idea of their capacity to install T2Dx systems? Assuming they get approval, how many systems can they install per month?
neals58 profile picture
This is going to be good
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.